AI
NTLA icon

Atria Investments’s Intellia Therapeutics NTLA Stock Holding History

Atria Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Buy
13,076
+2,684
+26% +$34.2K ﹤0.01% 1996
2025
Q4 		$93.4K Sell
10,392
-1
-0% -$14 ﹤0.01% 2007
2025
Q3 		$179K Buy
10,393
+176
+2% +$2.17K ﹤0.01% 1964
2025
Q2 		$95.8K Buy
+10,217
New +$83.9K ﹤0.01% 1967
2024
Q4 		– Sell
-23,099
Closed -$475K – 1943
2024
Q3 		$475K Buy
23,099
+4,511
+24% +$104K 0.01% 1352
2024
Q2 		$416K Buy
+18,588
New +$443K 0.01% 1399

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Atria Investments's NTLA Position: Q1 2026 in Review

Atria Investments increased its Intellia Therapeutics (NTLA) stake by 26% in Q1 2026, buying an estimated $34.2K and bringing the position to 13,076 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1996.

Atria Investments first reported a position in NTLA in Q2 2024 and has held it in 6 quarters since. The position peaked at $475K in Q3 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Atria Investments held 13,076 shares of Intellia Therapeutics worth $168K as of Q1 2026.
  • Atria Investments bought 2,684 Intellia Therapeutics shares in Q1 2026, an estimated $34.2K.
  • Intellia Therapeutics made up ﹤0.01% of Atria Investments's portfolio in Q1 2026, its #1996 holding.
  • Atria Investments first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Atria Investments's Intellia Therapeutics position peaked at $475K in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.